Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -11.31% is 64% above its 5-year average of -31.66%, near the high end of its 5-year range (-61.99%–1.88%).
32.28% below its 12-month average of -8.55%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.21%.
RETURN ON ASSETS (ROA)
-11.31%
RETURN ON ASSETS (ROA) AVG TTM
-8.55%
RETURN ON ASSETS (ROA) AVG 3Y
-34.29%
RETURN ON ASSETS (ROA) AVG 5Y
-31.66%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-32.28%
CURRENT VS 3Y AVG
+67.02%
CURRENT VS 5Y AVG
+64.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.07%
median of 561 covered companies
CURRENT VS SECTOR MEDIAN
+59.71%
vs the sector median at left
Alvotech
Market Cap
$2.07B
Return on Assets (ROA)
-11.31%
TTM Avg
-8.55%
3Y Avg
-34.29%
5Y Avg
-31.66%
Market Cap
$2.03B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$2.03B
Return on Assets (ROA)
-6.55%
TTM Avg
-5.28%
3Y Avg
-5.65%
5Y Avg
-2.06%
Market Cap
$2.10B
Return on Assets (ROA)
7.23%
TTM Avg
5.94%
3Y Avg
5.72%
5Y Avg
5.23%
Market Cap
$2.09B
Return on Assets (ROA)
-38.42%
TTM Avg
-32.16%
3Y Avg
-31.63%
5Y Avg
-27.96%
Market Cap
$2.00B
Return on Assets (ROA)
-52.34%
TTM Avg
-54.87%
3Y Avg
-41.09%
5Y Avg
-94.89%
Market Cap
$2.01B
Return on Assets (ROA)
14.58%
TTM Avg
11.33%
3Y Avg
2.89%
5Y Avg
-3.84%
Market Cap
$2.00B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
Market Cap
$2.02B
Return on Assets (ROA)
-11.00%
TTM Avg
-5.98%
3Y Avg
-9.46%
5Y Avg
-10.43%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.07B | -11.31% | -8.55% | -34.29% | -31.66% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | -68.96% | 16.60% | -13.89% | -23.58% |
| Azenta, Inc. (AZTA)vs › | $2.03B | -6.55% | -5.28% | -5.65% | -2.06% |
| Addus HomeCare Corporation (ADUS)vs › | $2.10B | 7.23% | 5.94% | 5.72% | 5.23% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | -38.42% | -32.16% | -31.63% | -27.96% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.00B | -52.34% | -54.87% | -41.09% | -94.89% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.01B | 14.58% | 11.33% | 2.89% | -3.84% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.00B | 39.65% | 19.63% | 0.51% | -8.90% |
| AxoGen, Inc. (AXGN)vs › | $2.02B | -11.00% | -5.98% | -9.46% | -10.43% |
| Immunome, Inc. (IMNM)vs › | $1.98B | -44.98% | -76.52% | -94.59% | -76.85% |
ROA
-11.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 1.88% |
| 2024-12-31 | -18.98% |
| 2023-12-31 | -58.07% |
| 2022-12-31 | -61.99% |
| 2021-12-31 | -16.97% |
| 2020-12-31 | -35.84% |
| 2019-12-31 | 0.00% |
